Ragnar Lunde

962 total citations
13 papers, 625 citations indexed

About

Ragnar Lunde is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ragnar Lunde has authored 13 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 5 papers in Radiation and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ragnar Lunde's work include Lung Cancer Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Advanced Radiotherapy Techniques (5 papers). Ragnar Lunde is often cited by papers focused on Lung Cancer Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Advanced Radiotherapy Techniques (5 papers). Ragnar Lunde collaborates with scholars based in Netherlands and Belgium. Ragnar Lunde's co-authors include Martijn A. Spruit, Ben E.E.M. van den Borne, Frank W.J.M. Smeenk, Emiel F.�M. Wouters, Lidwien Graat‐Verboom, Anne‐Marie C. Dingemans, Cordula Pitz, Wiel Geraedts, Angela van Baardwijk and Jacques Borger and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Respiratory Journal.

In The Last Decade

Ragnar Lunde

12 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ragnar Lunde Netherlands 9 515 141 139 128 87 13 625
Peter Lin Australia 15 216 0.4× 254 1.8× 40 0.3× 10 0.1× 56 0.6× 46 540
Colin Styles Australia 11 133 0.3× 110 0.8× 125 0.9× 72 0.6× 74 0.9× 23 385
Peter Bliss United Kingdom 10 161 0.3× 44 0.3× 46 0.3× 22 0.2× 55 0.6× 28 394
R.K. Shrimali India 11 118 0.2× 83 0.6× 85 0.6× 9 0.1× 73 0.8× 51 364
Francesca Chessa Italy 12 108 0.2× 246 1.7× 12 0.1× 51 0.4× 42 0.5× 31 539
Aalok Patel United States 15 720 1.4× 206 1.5× 65 0.5× 6 0.0× 276 3.2× 27 1.0k
Mehmet Kitapçı Türkiye 11 144 0.3× 195 1.4× 20 0.1× 8 0.1× 113 1.3× 23 441
Kiang‐Hiong Tay Singapore 9 220 0.4× 177 1.3× 108 0.8× 6 0.0× 34 0.4× 13 473
Carsten‐Oliver Sahlmann Germany 7 191 0.4× 131 0.9× 5 0.0× 22 0.2× 66 0.8× 13 433
Elisa D’Angelo Italy 14 214 0.4× 107 0.8× 117 0.8× 2 0.0× 81 0.9× 40 536

Countries citing papers authored by Ragnar Lunde

Since Specialization
Citations

This map shows the geographic impact of Ragnar Lunde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ragnar Lunde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ragnar Lunde more than expected).

Fields of papers citing papers by Ragnar Lunde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ragnar Lunde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ragnar Lunde. The network helps show where Ragnar Lunde may publish in the future.

Co-authorship network of co-authors of Ragnar Lunde

This figure shows the co-authorship network connecting the top 25 collaborators of Ragnar Lunde. A scholar is included among the top collaborators of Ragnar Lunde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ragnar Lunde. Ragnar Lunde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Hendriks, Lizza, Johanna H. M. Driessen, Guido M.J.M. Roemen, et al.. (2023). Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer. Frontiers in Oncology. 13. 1145001–1145001. 5 indexed citations
2.
Reymen, Bart, Angela van Baardwijk, Rinus Wanders, et al.. (2014). Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiotherapy and Oncology. 110(3). 482–487. 19 indexed citations
3.
Reymen, Bart, Judith van Loon, Angela van Baardwijk, et al.. (2012). Total Gross Tumor Volume Is an Independent Prognostic Factor in Patients Treated With Selective Nodal Irradiation for Stage I to III Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 85(5). 1319–1324. 34 indexed citations
4.
Baardwijk, Angela van, Bart Reymen, S. Wanders, et al.. (2012). Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. European Journal of Cancer. 48(15). 2339–2346. 52 indexed citations
5.
Steevens, Jessie, Dirk De Ruysscher, Anita A.M. Botterweck, et al.. (2011). Also elderly patients (75 years or older) with stage III non-small cell lung cancer (nsclc) have survival gains with radical treatment: a prospective population-based study. Journal of Thoracic Oncology. 6(6). 1 indexed citations
6.
Baardwijk, Angela van, Bart Reymen, Rinus Wanders, et al.. (2011). Results of a phase II trial on individualized radiation dose-escalation based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 6(6).
7.
Ruysscher, Dirk De, Angela van Baardwijk, Jessie Steevens, et al.. (2011). Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiotherapy and Oncology. 102(2). 228–233. 39 indexed citations
8.
Wanders, Rinus, Jessie Steevens, Anita A.M. Botterweck, et al.. (2011). Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: A prospective population-based study. European Journal of Cancer. 47(18). 2691–2697. 28 indexed citations
9.
Baardwijk, Angela van, S. Wanders, Liesbeth Boersma, et al.. (2010). Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(8). 1380–1386. 138 indexed citations
10.
Baardwijk, Angela van, Bart Reymen, Rinus Wanders, et al.. (2009). Individualized radiation dose escalation for stage I-III non-small cell lung cancer (NSCLC) based on normal tissue constraints: mature results of a phase II trial. Journal of Thoracic Oncology. 4(9). 1 indexed citations
11.
Graat‐Verboom, Lidwien, Martijn A. Spruit, Ben E.E.M. van den Borne, et al.. (2009). Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. Respiratory Medicine. 103(8). 1143–1151. 88 indexed citations
12.
Graat‐Verboom, Lidwien, Emiel F.�M. Wouters, Frank W.J.M. Smeenk, et al.. (2009). Current status of research on osteoporosis in COPD: a systematic review. European Respiratory Journal. 34(1). 209–218. 203 indexed citations
13.
Lunde, Ragnar, et al.. (2002). Right aortic arch symptomatic in adulthood.. PubMed. 60(5). 212–5. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026